ArticleVaccines2022
A Bivalent MAPS Vaccine Induces Protective Antibody Responses against
Article in Vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 15 citations in OpenAlex.
- Development and validation of immunological assays for preclinical evaluation of a novel bivalent typhoid conjugate vaccine.Human vaccines & immunotherapeutics · 2026Article
- Understanding the impact of Klebsiella pneumoniae K-Antigen based MAPS vaccine design on the immune response in animal models.PLoS pathogens · 2026Article
- Immunoprophylactic potential against pneumonia caused by indigenous isolates of Klebsiella pneumoniae and Streptococcus pneumoniae in experimental mice.Scientific reports · 2026Article
- Immunogenicity of an inactivated vaccine against senecavirus a and duration of the immune response in pigs.Archives of virology · 2026Article
- Preclinical evaluation of a bivalent conjugate vaccine againstFrontiers in immunology · 2026Article
- Development of an 8-valentFrontiers in immunology · 2026Article
- Characterization of a Luminescence-Based Serum Bactericidal Activity Assay for Human Sera Against a Panel ofMicroorganisms · 2025Article
- Non-typhoidal Salmonella combination vaccines: clinical development plan and regulatory considerations.Vaccine · 2025Review
- Assessing Salmonella Typhi Pathogenicity and Prevention: The Crucial Role of Vaccination in Combating Typhoid Fever.International journal of molecular sciences · 2025Review
- Evaluation of a QuadrivalentVaccines · 2024Article
- Typhoid & paratyphoid vaccine development in the laboratory: a review & in-country experience.The Indian journal of medical research · 2024Review
- Article
- Evolution of Vaccines Formulation to Tackle the Challenge of Anti-Microbial Resistant Pathogens.International journal of molecular sciences · 2023Review
- Exploring the variables influencing the immune response of traditional and innovative glycoconjugate vaccines.Frontiers in molecular biosciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infections by Salmonella Typhi and Paratyphi A strain are still a major cause of morbidity and mortality in developing countries. Generation of antibodies against the Vi capsular polysaccharide of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.